Class information for:
Level 1: XANOMELINE//M 1//ALCURONIUM

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
10380 1069 47.1 84%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
405 3       BACTERIORHODOPSIN//G PROTEIN COUPLED RECEPTOR//G PROTEIN 29641
705 2             G PROTEIN COUPLED RECEPTOR//GPCR//RHODOPSIN 12950
10380 1                   XANOMELINE//M 1//ALCURONIUM 1069

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 XANOMELINE authKW 686209 3% 78% 31
2 M 1 authKW 330176 2% 68% 17
3 ALCURONIUM authKW 283942 1% 76% 13
4 VANDERBILT NEUROSCI DRUG DISCOVERY address 215007 4% 19% 39
5 MUSCARINIC authKW 210125 6% 11% 65
6 MUSCARINIC RECEPTORS authKW 201355 13% 5% 135
7 DRUG DISCOVERY BIOL address 189874 3% 21% 32
8 ALLOSTERIC ENHANCER authKW 182799 1% 80% 8
9 MUSCARINIC ACETYLCHOLINE RECEPTOR 1 authKW 174946 1% 88% 7
10 REBECCA L COOPER S address 171668 2% 26% 23

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Pharmacology & Pharmacy 7171 48% 0% 512
2 Chemistry, Medicinal 3699 18% 0% 191
3 Neurosciences 2042 27% 0% 287
4 Psychiatry 1433 14% 0% 150
5 Chemistry, Organic 211 8% 0% 85
6 Clinical Neurology 158 7% 0% 73
7 Biochemistry & Molecular Biology 93 12% 0% 133
8 Medicine, Research & Experimental 35 3% 0% 36
9 Behavioral Sciences 14 1% 0% 14
10 Geriatrics & Gerontology 8 1% 0% 8

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 VANDERBILT NEUROSCI DRUG DISCOVERY 215007 4% 19% 39
2 DRUG DISCOVERY BIOL 189874 3% 21% 32
3 REBECCA L COOPER S 171668 2% 26% 23
4 MOL PSYCHIAT S 142814 0% 100% 5
5 NEUROSCI INNOVAT MED 102007 0% 71% 5
6 VANDERBILT PROGRAM DRUG DISCOVERY 96186 1% 21% 16
7 SEZ CHIM FARMACEUT PIETRO PRATESI 87466 1% 44% 7
8 MONASH PHARMACEUT SCI 86695 6% 5% 65
9 MOL CELLULAR PHARMACOBIOL SECT 76157 1% 33% 8
10 DEV DISCOVERY 57126 0% 100% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MOLECULAR PHARMACOLOGY 24752 9% 1% 92
2 ACS CHEMICAL NEUROSCIENCE 6124 1% 2% 14
3 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 4981 6% 0% 61
4 JOURNAL OF MEDICINAL CHEMISTRY 3960 5% 0% 55
5 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 3239 5% 0% 54
6 INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 2717 1% 1% 13
7 TRENDS IN PHARMACOLOGICAL SCIENCES 1867 1% 0% 15
8 EUROPEAN JOURNAL OF PHARMACOLOGY 1820 4% 0% 43
9 NEUROPSYCHOPHARMACOLOGY 1600 2% 0% 17
10 SCHIZOPHRENIA RESEARCH 1225 1% 0% 16

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 XANOMELINE 686209 3% 78% 31 Search XANOMELINE Search XANOMELINE
2 M 1 330176 2% 68% 17 Search M+1 Search M+1
3 ALCURONIUM 283942 1% 76% 13 Search ALCURONIUM Search ALCURONIUM
4 MUSCARINIC 210125 6% 11% 65 Search MUSCARINIC Search MUSCARINIC
5 MUSCARINIC RECEPTORS 201355 13% 5% 135 Search MUSCARINIC+RECEPTORS Search MUSCARINIC+RECEPTORS
6 ALLOSTERIC ENHANCER 182799 1% 80% 8 Search ALLOSTERIC+ENHANCER Search ALLOSTERIC+ENHANCER
7 MUSCARINIC ACETYLCHOLINE RECEPTOR 1 174946 1% 88% 7 Search MUSCARINIC+ACETYLCHOLINE+RECEPTOR+1 Search MUSCARINIC+ACETYLCHOLINE+RECEPTOR+1
8 ALLOSTERIC MODULATOR 157358 4% 15% 38 Search ALLOSTERIC+MODULATOR Search ALLOSTERIC+MODULATOR
9 M 5 155506 1% 78% 7 Search M+5 Search M+5
10 ALLOSTERIC MODULATION 150331 3% 14% 37 Search ALLOSTERIC+MODULATION Search ALLOSTERIC+MODULATION

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 DAVIE, BJ , CHRISTOPOULOS, A , SCAMMELLS, PJ , (2013) DEVELOPMENT OF M-1 MACHR ALLOSTERIC AND BITOPIC LIGANDS: PROSPECTIVE THERAPEUTICS FOR THE TREATMENT OF COGNITIVE DEFICITS.ACS CHEMICAL NEUROSCIENCE. VOL. 4. ISSUE 7. P. 1026-1048 106 75% 24
2 GREGORY, KJ , SEXTON, PM , CHRISTOPOULOS, A , (2007) ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTORS.CURRENT NEUROPHARMACOLOGY. VOL. 5. ISSUE 3. P. 157-167 76 74% 35
3 KRUSE, AC , KOBILKA, BK , GAUTAM, D , SEXTON, PM , CHRISTOPOULOS, A , WESS, J , (2014) MUSCARINIC ACETYLCHOLINE RECEPTORS: NOVEL OPPORTUNITIES FOR DRUG DEVELOPMENT.NATURE REVIEWS DRUG DISCOVERY. VOL. 13. ISSUE 7. P. 549 -560 64 55% 53
4 BIRDSALL, NJM , LAZARENO, S , (2005) ALLOSTERISM AT MUSCARINIC RECEPTORS: LIGANDS AND MECHANISMS.MINI-REVIEWS IN MEDICINAL CHEMISTRY. VOL. 5. ISSUE 6. P. 523-543 93 60% 79
5 DENCKER, D , THOMSEN, M , WORTWEIN, G , WEIKOP, P , CUI, YH , JEON, J , WESS, J , FINK-JENSEN, A , (2012) MUSCARINIC ACETYLCHOLINE RECEPTOR SUBTYPES AS POTENTIAL DRUG TARGETS FOR THE TREATMENT OF SCHIZOPHRENIA, DRUG ABUSE, AND PARKINSON'S DISEASE.ACS CHEMICAL NEUROSCIENCE. VOL. 3. ISSUE 2. P. 80 -89 66 72% 9
6 MOHR, K , TRANKLE, C , HOLZGRABE, U , (2003) STRUCTURE/ACTIVITY RELATIONSHIPS OF M-2 MUSCARINIC ALLOSTERIC MODULATORS.RECEPTORS & CHANNELS. VOL. 9. ISSUE 4. P. 229-240 61 90% 20
7 MELANCON, BJ , TARR, JC , PANARESE, JD , WOOD, MR , LINDSLEY, CW , (2013) ALLOSTERIC MODULATION OF THE M-1 MUSCARINIC ACETYLCHOLINE RECEPTOR: IMPROVING COGNITION AND A POTENTIAL TREATMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE.DRUG DISCOVERY TODAY. VOL. 18. ISSUE 23-24. P. 1185-1199 54 64% 26
8 KUDUK, SD , BESHORE, DC , (2012) NOVEL M-1 ALLOSTERIC LIGANDS: A PATENT REVIEW.EXPERT OPINION ON THERAPEUTIC PATENTS. VOL. 22. ISSUE 12. P. 1385-1398 41 91% 16
9 CARRUTHERS, SP , GURVICH, CT , ROSSELL, SL , (2015) THE MUSCARINIC SYSTEM, COGNITION AND SCHIZOPHRENIA.NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. VOL. 55. ISSUE . P. 393 -402 73 45% 7
10 DIGBY, GJ , SHIREY, JK , CONN, PJ , (2010) ALLOSTERIC ACTIVATORS OF MUSCARINIC RECEPTORS AS NOVEL APPROACHES FOR TREATMENT OF CNS DISORDERS.MOLECULAR BIOSYSTEMS. VOL. 6. ISSUE 8. P. 1345 -1354 62 59% 31

Classes with closest relation at Level 1


Rank Class id link
1 1278 MUSCARINIC RECEPTOR SUBTYPES//MUSCARINIC RECEPTORS//PIRENZEPINE
2 26532 AGONIST AFFINITY//ANTAGONIST DISSOCIATION CONSTANTS//IRREVERSIBLE RECEPTOR INACTIVATION METHOD
3 26108 BIOCHEM TECHNOL SCI TECHNOL//GPR35//RESONANT WAVEGUIDE GRATING BIOSENSOR
4 4196 G PROTEIN COUPLED RECEPTOR//GPCR//MEMBRANE PROT STRUCT FUNCT UNIT
5 21950 FP TZTP//IQNP//N C 11METHYL 3 PIPERIDYL BENZILATE
6 35587 GALBULIMIMA ALKALOIDS//GALBULIMIMA BELGRAVEANA//HIMBACINE
7 9142 RECEPTOR MOSAICS//HETEROMER//RECEPTOR RECEPTOR INTERACTIONS
8 32378 FLUORESCENT LIGANDS//1012 S//ALEXA FLUOR R 647
9 22984 CHOLINERG NEUROPHARMACOL//PRESYNAPTIC D 2 DOPAMINE RECEPTOR//192 IGG SAPORIN AND P75
10 12662 CHRNA7//ALPHA 7//ALPHA 7 NICOTINIC RECEPTOR

Go to start page